Windlas Biotech Limited
Windlas Biotech Limited scores highest on Earnings (70) and lowest on Nitro (45). Its PosiPenta is 60.05 out of 100, better than most similar companies.
Compared with similar companies in the Healthcare sector in India.
The five pillars
Details
PPrice
| P/E ratio | 27.92 |
| P/B ratio | 3.10 |
EEarnings
| Trailing EPS | ₹31.26 |
| Forward EPS | — |
NNitro
| Price | 872.70 |
| 52-week high | 1181.90 |
| 52-week low | 697.40 |
| Fall from 52-week high | 26.2% |
TTorque
| Return on equity (ROE) (calculated) | 11.11% |
| Debt-to-equity | 0.06 |
AAnchor
| Beta (price swings) | 0.26 |
| Market cap | ₹1,800 Cr |
| Promoter holding | 63.31% |
| Dividend yield | 0.67% |
Figures as used for the week of 24 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Windlas Biotech Limited's PosiPenta score?
Windlas Biotech Limited's PosiPenta is 60.05 out of 100 for the week of 24 Oct 2026, based on 5 of 5 pillars.
Which PosiPenta pillar is strongest for Windlas Biotech Limited?
Earnings (growth), with a score of 70 out of 100: better than most similar companies.
Which PosiPenta pillar is weakest for Windlas Biotech Limited?
Nitro (momentum), with a score of 45 out of 100: around the middle of similar companies.
Has Windlas Biotech Limited's PosiPenta changed since last week?
Yes, it rose 0.03 points, from 60.02 to 60.05.
PositoAI is for research and education only and is not investment advice.